270 related articles for article (PubMed ID: 34453542)
21. HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants.
Smith SJ; Zhao XZ; Passos DO; Lyumkis D; Burke TR; Hughes SH
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32601157
[TBL] [Abstract][Full Text] [Related]
22. HIV-1 non-group M phenotypic susceptibility in vitro to bictegravir and cabotegravir.
Martin C; Gracias S; Charpentier C; Descamps D; Le Hingrat Q; Plantier JC; Alessandri-Gradt E
J Antimicrob Chemother; 2021 Aug; 76(9):2306-2309. PubMed ID: 34151963
[TBL] [Abstract][Full Text] [Related]
23. A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain.
Le Hingrat Q; Collin G; Lê M; Peytavin G; Visseaux B; Bertine M; Tubiana R; Karmochkine M; Valin N; Collin F; Lemaignen A; Bernard L; Damond F; Matheron S; Descamps D; Charpentier C;
Clin Infect Dis; 2019 Aug; 69(4):657-667. PubMed ID: 30383215
[TBL] [Abstract][Full Text] [Related]
24. Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.
Seki T; Suyama-Kagitani A; Kawauchi-Miki S; Miki S; Wakasa-Morimoto C; Akihisa E; Nakahara K; Kobayashi M; Underwood MR; Sato A; Fujiwara T; Yoshinaga T
Antimicrob Agents Chemother; 2015 May; 59(5):2596-606. PubMed ID: 25691633
[TBL] [Abstract][Full Text] [Related]
25. Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors.
Hachiya A; Kirby KA; Ido Y; Shigemi U; Matsuda M; Okazaki R; Imamura J; Sarafianos SG; Yokomaku Y; Iwatani Y
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533248
[TBL] [Abstract][Full Text] [Related]
26. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
Requena S; Treviño A; Cabezas T; Garcia-Delgado R; Amengual MJ; Lozano AB; Peñaranda M; Fernández JM; Soriano V; de Mendoza C;
J Antimicrob Chemother; 2017 Jul; 72(7):2083-2088. PubMed ID: 28369593
[TBL] [Abstract][Full Text] [Related]
27. Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance.
Richetta C; Tu NQ; Delelis O
Viruses; 2022 Nov; 14(12):. PubMed ID: 36560595
[TBL] [Abstract][Full Text] [Related]
28. Primary resistance to integrase inhibitors in Shenzhen.
Zhu Y; Huang Y; Zheng C; Tang J; Zeng G; Xie W; Wang H; Zhang L; Liu S; Zhang Y; Tan W; Tan J; Jiang L; He Y; Xu L; Yang Z; Zhao J
J Antimicrob Chemother; 2023 Feb; 78(2):546-549. PubMed ID: 36585770
[TBL] [Abstract][Full Text] [Related]
29. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
Fourati S; Charpentier C; Amiel C; Morand-Joubert L; Reigadas S; Trabaud MA; Delaugerre C; Nicot F; Rodallec A; Maillard A; Mirand A; Jeulin H; Montès B; Barin F; Bettinger D; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Descamps D; Calvez V; Flandre P; Marcelin AG;
J Antimicrob Chemother; 2015 May; 70(5):1507-12. PubMed ID: 25558077
[TBL] [Abstract][Full Text] [Related]
30. HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance.
Mbhele N; Chimukangara B; Gordon M
Int J Antimicrob Agents; 2021 May; 57(5):106343. PubMed ID: 33852932
[TBL] [Abstract][Full Text] [Related]
31. Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants.
Smith SJ; Zhao XZ; Burke TR; Hughes SH
Retrovirology; 2018 May; 15(1):37. PubMed ID: 29769116
[TBL] [Abstract][Full Text] [Related]
32. Virological outcomes of various first-line ART regimens in patients harbouring HIV-1 E157Q integrase polymorphism: a multicentre retrospective study.
Uno S; Gatanaga H; Hayashida T; Imahashi M; Minami R; Koga M; Samukawa S; Watanabe D; Fujii T; Tateyama M; Nakamura H; Matsushita S; Yoshino Y; Endo T; Horiba M; Taniguchi T; Moro H; Igari H; Yoshida S; Teshima T; Nakajima H; Nishizawa M; Yokomaku Y; Iwatani Y; Hachiya A; Kato S; Hasegawa N; Yoshimura K; Sugiura W; Kikuchi T
J Antimicrob Chemother; 2023 Dec; 78(12):2859-2868. PubMed ID: 37856677
[TBL] [Abstract][Full Text] [Related]
33. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
[TBL] [Abstract][Full Text] [Related]
34. Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey.
Cecchini DM; Castillo S; Copertari G; Lacal V; Rodriguez CG; Cassetti I
Rev Esp Quimioter; 2019 Jun; 32(3):263-267. PubMed ID: 31037930
[TBL] [Abstract][Full Text] [Related]
35. Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.
Hassounah SA; Liu Y; Quashie PK; Oliveira M; Moisi D; Brenner BG; Sandstrom PA; Mesplède T; Wainberg MA
J Virol; 2015 Dec; 89(23):12002-13. PubMed ID: 26378179
[TBL] [Abstract][Full Text] [Related]
36. Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors.
Yang LL; Li Q; Zhou LB; Chen SQ
Int J Antimicrob Agents; 2019 Nov; 54(5):547-555. PubMed ID: 31398480
[TBL] [Abstract][Full Text] [Related]
37. High Instantaneous Inhibitory Potential of Bictegravir and the New Spiro-β-Lactam BSS-730A for HIV-2 Isolates from RAL-Naïve and RAL-Failing Patients.
Bártolo I; Moranguinho I; Gonçalves P; Diniz AR; Borrego P; Martin F; Figueiredo I; Gomes P; Gonçalves F; Alves AJS; Alves N; Caixas U; Pinto IV; Barahona I; Pinho E Melo TMVD; Taveira N
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430777
[TBL] [Abstract][Full Text] [Related]
38. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.
Abram ME; Hluhanich RM; Goodman DD; Andreatta KN; Margot NA; Ye L; Niedziela-Majka A; Barnes TL; Novikov N; Chen X; Svarovskaia ES; McColl DJ; White KL; Miller MD
Antimicrob Agents Chemother; 2013 Jun; 57(6):2654-63. PubMed ID: 23529738
[TBL] [Abstract][Full Text] [Related]
39. Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.
Hachiya A; Ode H; Matsuda M; Kito Y; Shigemi U; Matsuoka K; Imamura J; Yokomaku Y; Iwatani Y; Sugiura W
Antiviral Res; 2015 Jul; 119():84-8. PubMed ID: 25956162
[TBL] [Abstract][Full Text] [Related]
40. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.
Fransen S; Gupta S; Danovich R; Hazuda D; Miller M; Witmer M; Petropoulos CJ; Huang W
J Virol; 2009 Nov; 83(22):11440-6. PubMed ID: 19759152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
